Global Hemophilia Drugs Market to grow at a CAGR of 4.76% during Forecast 2016-2020

Latest Research Report titled " Global Hemophilia Drugs Market 2016-2020 " features Key Market Players, Survey, Growth, Challenges and Forecast.

Hemophilia is an X-linked genetic disorder that results in excessive blood loss during an injury, causing fatigue or even death. The disorder is more common in males and affects roughly 400,000 people globally every year. Hemophilia A is the more common form of this disorder, while hemophilia B is the rare form of hemophilia. To mitigate this disorder, plasma-derived clotting factors or recombinant clotting factors have been developed and are administered to the affected individual. The therapy is usually done in two ways: short acting therapeutic and long-acting therapeutic.

The global hemophilia drugs market to grow at a CAGR of 4.76% during the period 2016-2020. The report covers the present scenario and the growth prospects of the global hemophilia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of of drugs used for the treatment of hemophilia, including hemophilia A, hemophilia B, and inhibitors.

The market is divided into the following segments based on geography:
- Americas
- APAC
- EMEA

Get a Sample Research PDF with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=850971

Technavio's report, Global Hemophilia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
- Baxalta
- Bayer
- CSL Behring
- Novo Nordisk
- Pfizer

Other prominent vendors
- Alnylam Pharmaceuticals
- Amarna Therapeutics
- Asklepios BioPharmaceutical
- Biogen
- BioMarin
- Catalyst Bioscience
- Chiesi Farmaceutici
- Dimension Therapeutics
- Emergent BioSolutions
- F. Hoffmann-La Roche
- Grifols, Kedrion Biopharma
- Octapharma
- rEVO Biologics
- OPKO Biologics
- Sangamo Biosciences
- Spark Therapeutics
- Swedish Orphan Biovitrum
- UniQure Biopharma.

Market driver
- Focus on prophylactic treatment
- For a full, detailed list, view our report

Market challenge
- Low diagnosis rate
- For a full, detailed list, view our report

Key questions answered in this report
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

About Us

ResearchMoz is the world’s fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz’s service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

This release was published on openPR.